Prasugrel Tablet
Description
PRASUROOT-10
Prasugrel Hydrochloride 10 mg Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Prasugrel Hydrochloride IP equivalent to Prasugrel — 10 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
PRASUROOT-10 contains Prasugrel Hydrochloride 10 mg, a potent third-generation antiplatelet agent formulated for the prevention of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS), coronary artery disease, and post-percutaneous coronary intervention (PCI). Prasugrel provides rapid, potent, and consistent platelet inhibition, significantly reducing the risk of myocardial infarction, stent thrombosis, ischemic stroke, and recurrent cardiovascular events.
Prasugrel is widely prescribed in cardiology for patients with ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), unstable angina, coronary stenting, and high-risk ischemic cardiovascular disease. It is commonly used as part of dual antiplatelet therapy (DAPT) in combination with aspirin for long-term secondary prevention of cardiovascular events.
PRASUROOT-10 is particularly beneficial for patients undergoing PCI, post-coronary stenting, acute coronary syndrome, diabetes-associated coronary artery disease, and individuals requiring intensive and sustained platelet inhibition.
Technical Knowledge of Prasugrel
Prasugrel is a prodrug that undergoes rapid hepatic activation to form an active metabolite that irreversibly inhibits the platelet P2Y12 ADP receptor. This blocks ADP-mediated activation of the GPIIb/IIIa receptor complex, resulting in potent inhibition of platelet aggregation and arterial thrombus formation.
Prasugrel produces rapid onset of action, consistent platelet inhibition, and lower interpatient variability compared with several earlier P2Y12 inhibitors. Its irreversible receptor inhibition provides sustained antiplatelet activity for the lifespan of affected platelets.
Mechanism of Action
Prasugrel irreversibly inhibits the platelet P2Y12 ADP receptor, blocks ADP-mediated platelet activation, prevents GPIIb/IIIa receptor activation, inhibits platelet aggregation, and reduces arterial thrombus formation.
Key Benefits
Potent and rapid platelet inhibition
Reduces the risk of myocardial infarction
Helps prevent stent thrombosis
Reduces recurrent ischemic cardiovascular events
Provides consistent antiplatelet efficacy
Effective in acute coronary syndrome
Supports long-term secondary cardiovascular prevention
Suitable for post-PCI antiplatelet management under medical supervision
Clinical Applications
PRASUROOT-10 is commonly prescribed for acute coronary syndrome, post-percutaneous coronary intervention, post-coronary stenting, STEMI, NSTEMI, unstable angina, coronary artery disease, diabetic cardiovascular disease, and secondary prevention of recurrent cardiovascular events.
Facts About Prasugrel
Prasugrel is a highly effective P2Y12 receptor inhibitor with extensive clinical evidence supporting reduction of ischemic events and stent thrombosis in ACS patients undergoing PCI. It provides rapid and consistent platelet inhibition and is recommended in major international cardiology guidelines for appropriate patients with acute coronary syndrome treated with coronary intervention.
Key Facts
Third-generation P2Y12 receptor inhibitor
Prasugrel 10 mg for potent antiplatelet therapy
Rapid and sustained platelet inhibition
Reduces stent thrombosis and recurrent ischemic events
Essential therapy after PCI and acute coronary syndrome
Evidence-based cardiovascular antiplatelet therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
PRASUROOT-10 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of coronary artery disease, acute coronary syndrome, diabetes, hypertension, and coronary interventions creates strong prescription demand and long-term market potential for this formulation.
Why Choose PRASUROOT-10 for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Prasugrel Hydrochloride 10 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
PRASUROOT-10 from DIABGLYM combines potent antiplatelet protection, evidence-based cardiovascular therapy, comprehensive thrombotic risk reduction, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Prasugrel formulation.
